micro-community-banner
 
  • Saved

3yr
Optical coherence tomography for monitoring biologic therapy in psoriasis and atopic dermatitis: A case series

Optical coherence tomography for monitoring biologic therapy in psoriasis and atopic dermatitis: A case series

Source : https://www.frontiersin.org/articles/10.3389/fmed.2022.995883/abstract

Biologic therapies are increasingly used to treat chronic inflammatory skin diseases such as psoriasis and atopic dermatitis. In clinical practice, scores based on evaluation of objective and subjective symptoms are...


Discussion: Imaging parameters may enable objective quantification of inflammation in psoriasis or atopic dermatitis in selected representative skin areas. OCT may reveal persistent subclinical inflammation in atopic dermatitis beyond clinical remission.

  • Saved

3yr
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Source : https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01539-2/fulltext

Dupilumab significantly improved atopic dermatitis signs and symptoms versus placebo in children younger than 6 years. Dupilumab was well tolerated and showed an acceptable safety profile, similar to results in...


Conclusion: Dupilumab significantly improved atopic dermatitis signs and symptoms versus placebo in children younger than 6 years. Dupilumab was well tolerated and showed an acceptable safety profile, similar to results in older children and adults.

  • Saved

3yr
Biological therapy for young children with atopic dermatitis

Biological therapy for young children with atopic dermatitis

Source : https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01742-1/fulltext?rss=yes

Atopic dermatitis is a common inflammatory skin disease that might lead to severe and persistent disease during infancy. Atopic dermatitis is associated with poor school performance, psychiatric disease, and allergic...


Discussion: Oral medication can be challenging to use in children. Accordingly, there is a need for systemic therapies that are efficacious and have a favourable safety profile.

  • Saved

3yr
Navigating the treatment paradigms for atopic dermatitis

Atopic dermatitis (AD) symptoms fluctuate between stable disease and acute flare-ups. The step-up guidelines to better manage acute flare-ups, and worsening disease severity, include topical therapies for mild-to-moderate AD and systemic therapies for moderate-severe AD. Choosing different therapies is only one potential factor to improve patient outcomes. Non-adherence to treatment also limits patient outcomes for a variety of reasons, including lack of trust/understanding about disease management, inconvenience, and fear of side effects, among others.



Given an increasing range of therapeutic options for moderate AD, which include novel topical therapies, it may be useful to revisit the step-up paradigm.




  • What are the key factors to consider for mild-to-moderate AD treatment choices after disease flare-ups?

  • For moderate AD patients, when is a transition to additional/newer topical treatments preferable to oral therapies?


  • 3yr
    The key factors to determine therapies for patients are extent of disease, symptom severity, quality of life issues, patient desire for certain types of therapies, and access/affordability issues. With Show More
  • 3yr
    AD is a chronic autoimmune skin condition that fluctuates due to multiple environmental triggers and stressors. I have all AD patients optimize OTC care with mild cleansers and emollients, and Show More

Show More Comments

  • Saved

3yr
Navigating the treatment paradigms for atopic dermatitis

Atopic dermatitis (AD) symptoms fluctuate between stable disease and acute flare-ups. The step-up guidelines to better manage acute flare-ups, and worsening disease severity, include topical therapies for mild-to-moderate AD and systemic therapies for moderate-severe AD. Choosing different therapies is only one potential factor to improve patient outcomes. Non-adherence to treatment also limits patient outcomes for a variety of reasons, including lack of trust/understanding about disease management, inconvenience, and fear of side effects, among others.

Given an increasing range of therapeutic options for moderate AD, which include novel topical therapies, it may be useful to revisit the step-up paradigm.

  • What are the key factors to consider for mild-to-moderate AD treatment choices after disease flare-ups?
  • For moderate AD patients, when is a transition to additional/newer topical treatments preferable to oral therapies?
  • 3yr
    The key factors to determine therapies for patients are extent of disease, symptom severity, quality of life issues, patient desire for certain types of therapies, and access/affordability issues. With Show More
  • 3yr
    AD is a chronic autoimmune skin condition that fluctuates due to multiple environmental triggers and stressors. I have all AD patients optimize OTC care with mild cleansers and emollients, and Show More

Show More Comments